106539-36-0

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate is used as a building block for the synthesis of allylamines and N-Boc-β-amino acids, which are essential in the development of new pharmaceutical compounds. These synthesized compounds can be utilized in the treatment of various medical conditions, making this carbamate an important component in drug discovery and development.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate serves as a versatile building block for creating a wide range of chemical compounds. Its unique structure allows for various reactions, enabling the formation of complex molecules with potential applications in different industries, such as agriculture, materials science, and environmental science.

Upstream product

• 109208-68-6 Boc-Ala-O-COO-isoBu 
• 24424-99-5 di-tert-butyl dicarbonate 
• 61477-39-2 (+)-(S)-3-aminopropan-1-ol 
• 154079-54-6 (2S,3S)-3-tert-butoxycarbonylamino-1,2-butanediol 
• 158851-30-0 (S)-3-tert-butoxycarbonylaminobutyric acid 
• 67919-80-6 (S)-3-[(tert-butoxy)carbonylamino]-1-diazobutan-2-one 
• 15761-38-3 L-N-Boc-Ala 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 115378-33-1 (-)-tert-butyl [(1S)-1-methylprop-2-en-1-yl]carbamate 

Downstream Products

• 245124-02-1 (2S,4S)-N-(tert-Butoxycarbonyl)-2-cyclohexyl-4-methyltetrahydro-2H-1,3-oxazine 
• 106539-14-4 (S)-methyl 3-(tert-butyloxycarbonylamino)butyrate 
• 1344684-95-2 benzyl 4-{(3S)-3-[(tert-butoxycarbonyl)amino]butyl}piperazine-1-carboxylate 
• 106622-20-2 (3S)-1-bromo-t-butoxycarbonylbutan-3-ylamine 

Relevant academic research and scientific papers

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer. (II), or a pharmaceutically acceptable salt thereof, wherein: R1 is pyridin-3-yl, pyridin-4-yl, pyrazol-4-yl, cyclohexyl, or 8-azabicyclo[3.2.1]oct-2- ene-3-yl, wherein R1 is optionally substituted with up to four independently selected substituents; R2 is cyclohexyl substituted with hydroxy and optionally substituted with one or two additional substituents independently selected from C1-C4 alkyl and fluoro, or is 4,5,6,7- tetrahydro-lH-indazolyl optionally substituted with one to three substituents independently selected from C1-C4 alkyl and fluoro; and R3 is -C3-C8 alkyl, -(C2-C6 alkylene)-0-(C1-C6 alkyl), C3-C6 cycloalkyl, or -(C2-C6 alkylene)-C3-C6 cycloalkyl, wherein R3 is optionally substituted with 1-5 substituents inde endentl selected from deuterium, halo, and -OH.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Method for producing alcohols

A method for producing alcohols which comprises reducing esters or lactones with hydrogen gas in the presence of a catalyst comprising (i) a ruthenium compound, (ii) a monodentate monophosphine or a bidentate bisphosphine, and (iii) an amine. Examples of the catalyst include a ruthenium (Ru) complex represented by the formula:RuX1X2(LP)m(LN)n [X1 and X2 each represent an anionic ligand, LP represents a phosphine ligand, m is 1 when LP is bidentate, while m is 2 when LP is monodentate, LN represents an amine ligand, and n is 1 when LN is bidentate, while n is 2 when LN is monodentate.] and a catalyst comprising an amine and a ruthenium (Ru) complex of the formula: RuX1X2 (LP1)r [LP1 represents a monophosphine ligand and r is 3 or 4.].

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Substituted imidazole compounds

The present invention relates to novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as CSBP/p38 inhibitors.

Preparation and structure of homochiral tetrahydro-2H-l,3-oxazines

The synthesis, and structural elucidation using NMR and X-ray crystallography, of homochiral N-tert-butoxycarbonyl-tetrahydro-2H-1,3-oxazines are described.

A Concise Enantioselective Synthesis of Allylamines and N-Boc-β-Amino Acids

A new and efficient enantioselective synthesis of allylamines and N-Boc-β-amino acids has been developed.Starting from enantiomerically enriched N-diphenylmethyl-3-amino-1,2-diols, allylamines are easily obtained by a Corey-Hopkins deoxygenative protocol.After a change in the nitrogen protecting group, the resulting N-Boc allylamines are converted into β-amino acids by hydroboration with 9-BBN followed by oxidation with PDC in DMF.

Stereospecific Synthesis of (2R,5R)-Hept-6-yne-2,5-diamine: A Potent and Selective Enzyme-activated Irreversible Inhibitor of Ornithine Decarboxylase (ODC)

Hept-6-yne-2,5-diamine (2) and 2-methylhept-6-yne-2,5-diamine (3), while structurally related to the potent ornithine decarboxylase (ODC) inhibitor hex-5-yne-1,4-diamine (1), are stable to in vivo oxidation by monoamine oxidase (MAO).Although the methyl substitution is at a carbon relatively remote from the site of metabolic attack by ornithine decarboxylase (ODC), it has a critical influence on the potencies of these compounds as inhibitors of the enzyme.Of the four stereoisomers, (2R,5R)-(2) is the most active.Unambiguous syntheses of each isomer of (2) from the dianion of 3-trimethylsilyl-N-butoxycarbonylprop-2-ynylamine (5) are presented.